Stocks Health care ABBV
NYSE · Health careAbbVie Inc. (ABBV)
AbbVie Inc. brought in $64.4B of revenue over the twelve months to June 30, 2026, up 10.4% from a year earlier. Net income was $6.3B, a net margin of 9.8%. Operating cash flow minus capital spending left $17.8B of free cash flow in fiscal 2025. At June 30, 2026 it held $6.6B in cash against $70.8B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.
What AbbVie Inc. does
AbbVie Inc. is a biopharmaceutical company that discovers, develops, and sells prescription drugs. Its pharmaceutical portfolio includes treatments for immunology, oncology, neuroscience, eye care, and aesthetic medicine. Its well-known products include Humira, Skyrizi, Rinvoq, Imbruvica, and Botox. The company distributes its medicines through wholesalers, pharmacies, hospitals, and clinics. Its shares trade on NYSE under the ticker ABBV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $61.2B | $4.2B | $2.36 | $17.8B |
| 2024 | $56.3B | $4.3B | $2.39 | $17.8B |
| 2023 | $54.3B | $4.9B | $2.72 | $22.1B |
| 2022 | $58.1B | $11.8B | $6.63 | $24.2B |
| 2021 | $56.2B | $11.5B | $6.45 | $22B |
| 2020 | $45.8B | $4.6B | $2.72 | $16.8B |
Latest SEC filings
What AbbVie Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 3, 2026
- August 18, 2026Other event 8-K
- August 6, 2026
- August 5, 2026Other event 8-K
- August 5, 2026
- August 4, 2026
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026
- July 31, 2026
- July 6, 2026
- June 24, 2026
Questions about ABBV
What does AbbVie Inc. do?
AbbVie Inc. is a biopharmaceutical company that discovers, develops, and sells prescription drugs. Its pharmaceutical portfolio includes treatments for immunology, oncology, neuroscience, eye care, and aesthetic medicine. Its well-known products include Humira, Skyrizi, Rinvoq, Imbruvica, and Botox. The company distributes its medicines through wholesalers, pharmacies, hospitals, and clinics. Its shares trade on NYSE under the ticker ABBV.
Is AbbVie Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $6.3B on revenue of $64.4B, a net margin of 9.8%.
How much revenue does AbbVie Inc. make?
Over the twelve months to June 30, 2026 AbbVie Inc. reported revenue of $64.4B. That is 10.4% more than a year earlier.
When did AbbVie Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 3, 2026.
Similar companies
Follow ABBV
Get an email when AbbVie Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ABBV: get an email when it filesWhere the numbers come from
Financial figures are the values AbbVie Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.